Castle Biosciences
CSTL
89 hedge funds and large institutions have $219M invested in Castle Biosciences in 2020 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 37 increasing their positions, 14 reducing their positions, and 10 closing their positions.
220% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 10
164% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 14
33% more funds holding
Funds holding: 67 → 89 (+22)
25% more capital invested
Capital invested by funds: $176M → $219M (+$43.8M)
12.89% more ownership
Funds ownership: 29.93% → 42.81% (+13%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$8.45M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$8.26M |
| 3 |
TFS
TrustCore Financial Services
Brentwood,
Tennessee
|
+$7.81M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$7.68M |
| 5 |
Millennium Management
New York
|
+$6.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$5.13M |
| 2 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$1.86M |
| 3 |
ZP
Zimmer Partners
New York
|
-$1.75M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
-$1.52M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$1.24M |
CSTL Hedge Fund Activity: Q1 2020 in Review
89 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q1 2020, worth a combined $219M — up 25% from $176M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new CSTL positions and 10 closed out — a net gain of 22 holders — while 37 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $8.45M. The largest seller was Portolan Capital Management, cutting an estimated $5.13M.
- 89 institutional investors held Castle Biosciences (CSTL) as of Q1 2020, up from 67 in Q4 2019.
- Funds reported $219M of Castle Biosciences stock for Q1 2020, up 25% quarter-over-quarter.
- 32 funds opened new Castle Biosciences positions in Q1 2020 and 10 closed out, a net change of +22 holders.
- The largest Castle Biosciences buyer in Q1 2020 was BlackRock, an estimated $8.45M added.
- The largest Castle Biosciences seller in Q1 2020 was Portolan Capital Management, an estimated $5.13M sold.
Based on aggregated 13F filings for Q1 2020.